June 16, 2011
The State Biotechnology Industry Briefing is a PowerPoint presentation on the New York biotech industry that is made available to NYBA constituents for use in promoting the industry to a wider audience. Educators, analysts, business executives, entrepreneurs, financiers and others have used information from our industry briefings in various presentations relating to the industry.
Read More
June 16, 2011
Center for Biotechnology
Central New York Biotechnology Research Center
Columbia University Biomedical Informatics
Cornell University Institute for Biotechnology & Life Sciences Technologies New York Academy of Sciences
New York City Bioscience Initiative
New York State Assembly
New York State Department of Health
New York Biotechnology Association
New York State Legislature
Medical Society of the State of New York
Office of Governor Anthony Cuomo
June 16, 2011
September 19-21, 2011
Seaport World Trade Center
Boston, MA
Read More
June 16, 2011
September 19-21, 2011
Seaport World Trade Center
Boston, MA
Read More
June 16, 2011
September 7-9, 2011
Westin Boston Waterfront
Boston, MA
Read More
June 16, 2011
September 7-9, 2011
Westin Boston Waterfront
Boston, MA
Read More
June 16, 2011
June 2, 2011
Harvard Club of Boston, 374 Commonwealth Avenue
Boston, MA
Read More
June 16, 2011
March 7, 2011
Federal Reserve Bank of Boston; New England Room
Boston, MA
Read More
June 16, 2011
MassBio is front and center on Capitol Hill when it comes to advocating for policies that will pave the way for innovation. We fight for the laws and regulations that will speed the development of treatments and cures for Alzheimer’s, Diabetes, HIV/AIDs and other ailments. We work for policies that will help bring those drugs to the market and make them available to all.
Read More
June 16, 2011
Drugs developed through biotechnology differ from traditional small molecule chemical drugs. They are “biologics” that are complex medicines manufactured using living organisms. Biosimilars, also known as follow-on biologics are products that are similar to, but not the same as, an innovative new drug. They are not generic drugs, which are products shown to be the same as an innovative drug and generally designated as therapeutically interchangeable.
Read More
